PreciseDx® is dedicated to supporting more personalized and precise treatments for breast cancer. PreciseDx® is innovating oncology diagnostics, leveraging Artificial Intelligence (AI) for revolutionary, morphology-driven, disease analysis. Combining AI with our patented Morphology Feature Array® (MFA), PreciseDx provides access to unmatched disease insights and accurate, actionable intelligence for more comprehensive decision-making throughout the cancer care continuum. 

PreciseDx® is the only Cancer Risk Stratification company to provide patient-specific risk information through the analysis of morphology features, enabling better and more personalized treatment and outcomes. Clinical teams can rely on PreciseDx for unmatched insights and actionable intelligence in determining the best treatment for each patient.

PreciseDx’s AI-powered predictive platform creates disease-specific assays that deliver new levels of patient risk information to drive benefits across the healthcare continuum. Integrating artificial intelligence, lab processes and workflow systems. Transforming clinical modeling, patient phenotyping, and image analysis. Providing unmatched insights to support pathologists, and oncologists